



INVITATION

# TRANSPARENCY FOR INNOVATION AND ACCESS TO MEDICINES

Organised by the Global Health Centre at the Graduate Institute  
in collaboration with FIND

THE  
GRADUATE  
INSTITUTE  
GENEVA

GLOBAL  
HEALTH  
CENTRE



# GOVERNING GLOBAL HEALTH @WHA70

**PUBLIC EVENT**

**TUESDAY, 23 MAY 2017**

**15:00-16:30**

**MAISON DE LA PAIX, PETAL 2, AUDITORIUM**

## **What are the Benefits & Risks, Obstacles & Solutions?**

Recently, there has been increased attention to the issue of transparency in the pharmaceutical sector at national and global levels. Transparency was also a central theme of the United Nations Secretary-General's High-Level Panel on Access to Medicines report. Transparency is proposed in several fields related to innovation and access to medicines:

- Transparency on actual prices paid for medicines could address the asymmetric negotiating power between sellers and buyers of medicines (e.g. governments or other payers). However, concerns have been raised that price disclosure could increase prices in those countries that currently pay less than their peers.
- Access to accurate data on the costs of researching, developing and manufacturing medicines, as well as information on public and private contributions to R&D, could contribute to ensuring fairness of medicine prices and assessing the efficiency of R&D processes overall. However, it remains a subject of debate how cost estimates should be calculated and how such data could best be used in relevant policymaking.
- Complete, timely and accurate sharing of clinical trial results is critical for the ethical practice of medicine, regulatory decisions, and scientific progress, and particularly crucial during health emergencies. Although WHO has called for registration and publication of all interventional clinical trials and their results within a reasonable timeframe, some clinical trial results are still not publicly available. What additional measures are needed to improve transparency in this area?
- Greater transparency on patent status could reduce legal uncertainty with respect to where generic versions of medicines may be legally marketed, how patent standards are being applied, and the functioning of the patent system overall. What has been achieved and where do challenges remain in increasing patent transparency?

This event will bring together governments, industry, civil society and others to explore the potential of increasing transparency in the pharmaceutical sector and discuss the challenges and risks involved in the process.

15.00 - 15.10

WELCOME AND INTRODUCTION

Ilona **Kickbusch**

Director, Global Health Centre, the Graduate Institute

15.10 - 15.20

OPENING REMARKS

Tenu **Avafia**

HIV, Health and Development Group, United Nations Development Programme

15.20 - 16.00

PRESENTATIONS

Catharina **Boehme**

CEO, FIND

Clemens-Martin **Auer**

Director General, Austrian Federal Ministry of Health

Fumie **Griego**

Assistant Director General, International Federation of Pharmaceutical Manufacturers & Associations

James **Love**

Director, Knowledge Ecology International

Vasee **Moorthy**

Coordinator Research, Ethics, Knowledge Uptake, Health Systems and Innovation Cluster, World Health Organization

Moderator: Suerie **Moon**

Research Director, Global Health Centre, the Graduate Institute

16.00 - 16.30

DIALOGUE WITH THE PANEL AND THE AUDIENCE

THE  
GRADUATE  
INSTITUTE  
GENEVA

---

INSTITUT DE HAUTES  
ÉTUDES INTERNATIONALES  
ET DU DÉVELOPPEMENT

GRADUATE INSTITUTE  
OF INTERNATIONAL AND  
DEVELOPMENT STUDIES

For more information, please visit:

[🔗 graduateinstitute.ch/globalhealth-eventtransparency](https://graduateinstitute.ch/globalhealth-eventtransparency)  
or contact: [globalhealth@graduateinstitute.ch](mailto:globalhealth@graduateinstitute.ch)

You are required to register your attendance, free of charge, at

[🔗 graduateinstitute.ch/globalhealth-eventtransparency-registration](https://graduateinstitute.ch/globalhealth-eventtransparency-registration)